BR112022012222A2 - Derivados de piperazina substituídos úteis como ativadores de células t - Google Patents
Derivados de piperazina substituídos úteis como ativadores de células tInfo
- Publication number
- BR112022012222A2 BR112022012222A2 BR112022012222A BR112022012222A BR112022012222A2 BR 112022012222 A2 BR112022012222 A2 BR 112022012222A2 BR 112022012222 A BR112022012222 A BR 112022012222A BR 112022012222 A BR112022012222 A BR 112022012222A BR 112022012222 A2 BR112022012222 A2 BR 112022012222A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- piperazine derivatives
- substituted piperazine
- derivatives useful
- cell activators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201911053559 | 2019-12-23 | ||
| PCT/US2020/066504 WO2021133749A1 (en) | 2019-12-23 | 2020-12-22 | Substituted piperazine derivatives useful as t cell activators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022012222A2 true BR112022012222A2 (pt) | 2022-09-13 |
Family
ID=74191942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022012222A BR112022012222A2 (pt) | 2019-12-23 | 2020-12-22 | Derivados de piperazina substituídos úteis como ativadores de células t |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12454531B2 (https=) |
| EP (1) | EP4081522A1 (https=) |
| JP (1) | JP7712274B2 (https=) |
| KR (1) | KR20220120624A (https=) |
| CN (1) | CN115175907B (https=) |
| AU (1) | AU2020412698A1 (https=) |
| BR (1) | BR112022012222A2 (https=) |
| CA (1) | CA3162979A1 (https=) |
| IL (1) | IL294270A (https=) |
| MX (1) | MX2022007130A (https=) |
| WO (1) | WO2021133749A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT4081305T (lt) | 2019-12-24 | 2024-11-25 | Carna Biosciences, Inc. | Diacilglicerolio kinazę moduliuojantys junginiai |
| WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CA3222277A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2023122772A1 (en) * | 2021-12-22 | 2023-06-29 | Gossamer Bio Services, Inc. | Oxime derivatives useful as t cell activators |
| WO2023122777A1 (en) * | 2021-12-22 | 2023-06-29 | Gossamer Bio Services, Inc. | Oxime derivatives useful as t cell activators |
| CN114437127B (zh) * | 2022-01-28 | 2023-12-22 | 万华节能科技(烟台)有限公司 | 一种基于氧化膦衍生物改性异氰酸酯化合物及其合成方法 |
| EP4472963A1 (en) * | 2022-02-01 | 2024-12-11 | Arvinas Operations, Inc. | Dgk targeting compounds and uses thereof |
| KR20240156394A (ko) | 2022-03-01 | 2024-10-29 | 인실리코 메디신 아이피 리미티드 | 디아실글리세롤 키나아제 (dgk) 알파 억제제 및 이의 용도 |
| WO2023184327A1 (en) * | 2022-03-31 | 2023-10-05 | InventisBio Co., Ltd. | Kinase inhibitors, preparation methods and uses thereof |
| CN116969943A (zh) * | 2022-04-28 | 2023-10-31 | 轩竹生物科技股份有限公司 | 三并环类二酰甘油激酶抑制剂及其用途 |
| US12600722B2 (en) | 2022-07-18 | 2026-04-14 | Incyte Corporation | Tetracyclic compounds as DGK inhibitors |
| US12600723B2 (en) | 2022-07-18 | 2026-04-14 | Incyte Corporation | Tetracyclic compounds as DGK inhibitors |
| AR131786A1 (es) | 2023-02-06 | 2025-04-30 | Bayer Ag | Combinación de anticuerpos ccr8 con inhibidores de dgk |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4324893A (en) | 1979-04-18 | 1982-04-13 | American Home Products Corporation | 4-Amino-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives |
| JP2544939B2 (ja) | 1987-09-01 | 1996-10-16 | 大塚製薬株式会社 | ベンゾヘテロ環誘導体 |
| MY140679A (en) | 2001-05-24 | 2010-01-15 | Avanir Pharmaceuticals | Inhibitors of macrohage migration inhibitory factor and methods for identifying the same |
| WO2004002960A1 (en) | 2002-06-27 | 2004-01-08 | Schering Aktiengesellschaft | Substituted quinoline ccr5 receptor antagonists |
| GB0230018D0 (en) | 2002-12-23 | 2003-01-29 | Syngenta Ltd | Fungicides |
| TW200418829A (en) | 2003-02-14 | 2004-10-01 | Avanir Pharmaceutics | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| JP2006521400A (ja) | 2003-03-26 | 2006-09-21 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 糖尿病及び関連障害の処置のための化合物及びそれらの使用 |
| GB0316915D0 (en) | 2003-07-18 | 2003-08-20 | Glaxo Group Ltd | Compounds |
| AU2004259755A1 (en) | 2003-07-22 | 2005-02-03 | Janssen Pharmaceutica, N.V. | Quinolinone derivatives as inhibitors of c-fms kinase |
| EP1656376A1 (en) | 2003-08-22 | 2006-05-17 | Avanir Pharmaceuticals | Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases |
| US7381401B2 (en) | 2004-01-08 | 2008-06-03 | The University Of Chicago | T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| AU2006230099B2 (en) | 2005-03-25 | 2012-04-19 | Gitr, Inc. | GITR binding molecules and uses therefor |
| PL1879573T3 (pl) | 2005-05-10 | 2013-05-31 | Incyte Holdings Corp | Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| CA2634198C (en) | 2005-12-20 | 2014-06-03 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| GB0605689D0 (en) | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic compounds |
| WO2007114239A1 (ja) * | 2006-03-30 | 2007-10-11 | Sapporo Medical University | DGKα阻害剤を含有する抗癌剤 |
| JP2007308402A (ja) | 2006-05-17 | 2007-11-29 | Sumitomo Chemical Co Ltd | シンナモイル化合物及びその用途 |
| JP2007308441A (ja) | 2006-05-22 | 2007-11-29 | Sumitomo Chemical Co Ltd | 含複素環化合物及びその用途 |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| ES2444574T3 (es) | 2006-09-19 | 2014-02-25 | Incyte Corporation | N-hidroxiamidinoheterociclos como moduladores de la indolamina 2,3-dioxigenasa |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| ES2776406T3 (es) | 2007-07-12 | 2020-07-30 | Gitr Inc | Terapias de combinación que emplean moléculas de enlazamiento a GITR |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| JP5583592B2 (ja) | 2007-11-30 | 2014-09-03 | ニューリンク ジェネティクス コーポレイション | Ｉｄｏ阻害剤 |
| US20110176972A1 (en) | 2008-05-29 | 2011-07-21 | Saint-Gobain Centre De Recherches et D'Etudes Eur | Cellular structure containing aluminium titanate |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| US20110281908A1 (en) | 2008-10-06 | 2011-11-17 | Emory University | Aminoquinoline Derived Heat Shock Protein 90 Inhibitors, Methods Of Preparing Same, And Methods For Their Use |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| US20110319416A1 (en) | 2009-01-28 | 2011-12-29 | Emory University | Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions |
| EP2473531A4 (en) | 2009-09-03 | 2013-05-01 | Merck Sharp & Dohme | Anti-gitr antibodies |
| US8722720B2 (en) | 2009-10-28 | 2014-05-13 | Newlink Genetics Corporation | Imidazole derivatives as IDO inhibitors |
| PH12012500881A1 (en) | 2009-12-10 | 2017-07-26 | Hoffmann La Roche | Antibodies binding preferentially human csf1r extracellular domain 4 and their use |
| JP5998060B2 (ja) | 2010-03-04 | 2016-09-28 | マクロジェニクス，インコーポレーテッド | Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用 |
| CN102918061B (zh) | 2010-03-05 | 2016-06-08 | 霍夫曼-拉罗奇有限公司 | 针对人csf-1r的抗体及其用途 |
| CA2789076C (en) | 2010-03-05 | 2017-11-21 | F. Hoffmann-La Roche Ag | Antibodies against human colony stimulating factor-1 receptor and uses thereof |
| MX378336B (es) | 2010-05-04 | 2025-03-10 | Five Prime Therapeutics Inc | Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r). |
| EP2592933B1 (en) | 2010-07-16 | 2017-04-05 | Anderson Gaweco | Mif inhibitors and their uses |
| PT2614082T (pt) | 2010-09-09 | 2018-12-03 | Pfizer | Moléculas de ligação a 4-1bb |
| US9133164B2 (en) | 2011-04-13 | 2015-09-15 | Innov88 Llc | MIF inhibitors and their uses |
| NO2694640T3 (https=) | 2011-04-15 | 2018-03-17 | ||
| KR101970025B1 (ko) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들 |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| BR112014012624A2 (pt) | 2011-12-15 | 2018-10-09 | F Hoffmann-La Roche Ag | anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo |
| RU2014136332A (ru) | 2012-02-06 | 2016-03-27 | Дженентек, Инк. | Композиции и способы применения ингибиторов csf1r |
| WO2013118071A1 (en) | 2012-02-09 | 2013-08-15 | Glenmark Pharmaceuticals S.A. | BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| EP2847220A1 (en) | 2012-05-11 | 2015-03-18 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| WO2014039513A2 (en) | 2012-09-04 | 2014-03-13 | The Trustees Of The University Of Pennsylvania | Inhibition of diacylglycerol kinase to augment adoptive t cell transfer |
| MA41168A (fr) * | 2014-12-17 | 2017-10-24 | Acraf | Nouveaux composés antibactériens |
| JP2018513853A (ja) | 2015-04-10 | 2018-05-31 | アラクセス ファーマ エルエルシー | 置換キナゾリン化合物およびその使用方法 |
| CA3005766A1 (en) | 2015-12-17 | 2017-06-22 | Merck Patent Gmbh | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders |
| US10946020B2 (en) | 2016-04-06 | 2021-03-16 | University Of Virginia Patent Foundation | Compositions and methods for treating cancer |
| WO2018119183A2 (en) | 2016-12-22 | 2018-06-28 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| GB201700814D0 (en) | 2017-01-17 | 2017-03-01 | Liverpool School Tropical Medicine | Compounds |
| EA201992781A1 (ru) | 2017-05-22 | 2020-04-01 | Эмджен Инк. | Ингибиторы g12c kras и способы их применения |
| US12187687B2 (en) | 2017-06-26 | 2025-01-07 | University Of Virginia Patent Foundation | Compositions and uses thereof |
| WO2019062733A1 (zh) | 2017-09-28 | 2019-04-04 | 南京药捷安康生物科技有限公司 | Pde9 抑制剂及其用途 |
| WO2019213516A1 (en) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| PT3814347T (pt) * | 2018-06-27 | 2023-07-18 | Bristol Myers Squibb Co | Compostos de naftiridinona úteis como ativadores de células t |
| CN112654621B (zh) | 2018-06-27 | 2024-05-14 | 百时美施贵宝公司 | 可作为t细胞活化剂的经取代萘啶酮化合物 |
| JPWO2020071550A1 (ja) | 2018-10-04 | 2021-09-24 | 京都薬品工業株式会社 | Ｃｄｋ８阻害剤およびその用途 |
| AR119821A1 (es) | 2019-08-28 | 2022-01-12 | Bristol Myers Squibb Co | Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t |
| US20230064809A1 (en) | 2019-11-28 | 2023-03-02 | Bayer Aktiengesellschaft | Substituted aminoquinolones as dgkalpha inhibitors for immune activation |
| CN115210225A (zh) | 2019-11-28 | 2022-10-18 | 拜耳公司 | 取代的氨基喹诺酮类作为免疫激活的dgkalpha抑制剂 |
| KR20220122637A (ko) | 2019-11-28 | 2022-09-02 | 바이엘 악티엔게젤샤프트 | 면역 활성화를 위한 dgk알파 억제제로서의 치환된 아미노퀴놀론 |
-
2020
- 2020-12-22 EP EP20842856.5A patent/EP4081522A1/en active Pending
- 2020-12-22 AU AU2020412698A patent/AU2020412698A1/en not_active Abandoned
- 2020-12-22 JP JP2022538860A patent/JP7712274B2/ja active Active
- 2020-12-22 BR BR112022012222A patent/BR112022012222A2/pt not_active IP Right Cessation
- 2020-12-22 CN CN202080097016.2A patent/CN115175907B/zh active Active
- 2020-12-22 KR KR1020227025313A patent/KR20220120624A/ko active Pending
- 2020-12-22 WO PCT/US2020/066504 patent/WO2021133749A1/en not_active Ceased
- 2020-12-22 US US17/785,749 patent/US12454531B2/en active Active
- 2020-12-22 CA CA3162979A patent/CA3162979A1/en active Pending
- 2020-12-22 MX MX2022007130A patent/MX2022007130A/es unknown
- 2020-12-22 IL IL294270A patent/IL294270A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021133749A1 (en) | 2021-07-01 |
| CA3162979A1 (en) | 2021-07-01 |
| EP4081522A1 (en) | 2022-11-02 |
| IL294270A (en) | 2022-08-01 |
| MX2022007130A (es) | 2022-07-11 |
| US12454531B2 (en) | 2025-10-28 |
| US20230118629A1 (en) | 2023-04-20 |
| JP2023508375A (ja) | 2023-03-02 |
| CN115175907A (zh) | 2022-10-11 |
| JP7712274B2 (ja) | 2025-07-23 |
| CN115175907B (zh) | 2024-08-02 |
| KR20220120624A (ko) | 2022-08-30 |
| AU2020412698A1 (en) | 2022-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022012222A2 (pt) | Derivados de piperazina substituídos úteis como ativadores de células t | |
| BR112022012220A2 (pt) | Compostos de piperazina quinolinonil substituída úteis como ativadores de célula t | |
| MX2022002271A (es) | Compuestos de piridopirimidinonilo sustituidos utiles como activadores de celulas t. | |
| BR112022012179A2 (pt) | Compostos de quinazolina substituída úteis como ativadores de célula t | |
| BR112022012204A2 (pt) | Compostos de heteroarila substituída úteis como ativadores de célula t | |
| BR112022012195A2 (pt) | Derivados de piperidina bicíclico substituídos úteis como ativadores de células t | |
| EA202190137A1 (ru) | Нафтиридиноновые соединения для применения в качестве активаторов t-клеток | |
| BR112022009514A2 (pt) | Compostos úteis como inibidores de proteína helios | |
| CL2020003260A1 (es) | Compuestos de naftiridinona sustituidos útiles como activadores de células t | |
| EA202091491A1 (ru) | Новые бензиламинозамещенные пиридопиримидиноны и производные в качестве ингибиторов sos1 | |
| BR112022018706A2 (pt) | Compostos de oxoisoindolina substituída para tratamento de câncer | |
| BR112015031763A2 (pt) | Compostos, composição farmacêutica e processos para melhorar ou tratar infecção viral e para inibir a replicação de paramixovírus e usos de quantidade eficiente de composto ou sal farmaceuticamente aceitável do mesmo ou composição farmacêutica | |
| BR112015022462A8 (pt) | inibidores de ido, composição farmacêutica, método de inibição de atividade de indolamina 2,3-dioxigenase e uso dos referidos inibidores | |
| BR112015028879A8 (pt) | compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos | |
| PH12021500034A1 (en) | Compounds useful in hiv therapy | |
| BR112018005932A2 (pt) | inibidores de isoindolinona da interação de mdm2-p53 que têm atividade anticâncer | |
| GEP20237457B (en) | Nucleotide hemi-sulfate salt for treatment of hepatitis c virus | |
| BR112023020077A2 (pt) | Compostos de oxoisoindolina substituída por piridinila | |
| BR112017000246A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal | |
| BR112023020410A2 (pt) | Compostos de oxoisoindolina substituída por piridinila para tratamento de câncer | |
| BR112017005242A2 (pt) | composto, composição farmacêutica, e, composto para uso. | |
| BR112019018615A2 (pt) | compostos antimicrobianos, composições e usos dos mesmos | |
| BR112022001390A2 (pt) | Inibidores de enzima | |
| AU2020353055A8 (en) | Antiviral pyrazolopyridinone compounds | |
| BR112021025618A2 (pt) | Composto, método para prevenir, tratar ou diminuir a gravidade de uma doença, composição farmacêutica e uso de um composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2860 DE 28-10-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |